CLDXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Celldex Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$29.67+2.14 (+7.77%)
Close on Oct 19, 2026
- Market cap
- $2.31B
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
86M of 79M shares
Institutional holders
253
49 new, 21 sold out
Net institutional buying
13M
In Q2 2026
Insider trades, 12 months
0 buys · 2 sales
Net sold $1.30M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Abigail P. Johnson | 8,411,905 | 10.70% | 13G (passive) amendment | Sep 30, 2026 |
| Wellington Management Group LLP | 8,079,608 | 12.20% | 13G (passive) amendment | Dec 31, 2025 |
| Wellington Group Holdings LLP | 5,232,326 | 7.90% | 13G (passive) amendment | Jun 30, 2025 |
| FMR LLC | 4,857,668 | 7.30% | 13G (passive) amendment | Dec 31, 2024 |
| BlackRock, Inc. | 4,819,293 | 7.30% | 13G (passive) amendment | Mar 31, 2025 |
| T. Rowe Price Associates, Inc. | 4,686,187 | 6.00% | 13G (passive) | Jun 30, 2026 |
| Point72 Capital Advisors, Inc. | 4,464,400 | 6.70% | 13G (passive) | Jul 2, 2025 |
| Vanguard Capital Management | 3,446,795 | 5.17% | 13G (passive) | Mar 31, 2026 |
| Kynam Capital Management, LP | 0 | 6.78% | 13G (passive) amendment | Jun 30, 2026 |
| Kynam Capital Management GP, LLC | 0 | 8.77% | 13G (passive) amendment | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CLDX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Wellington Management Group Llp | 9,543,671 | 12.15% | $355.12M | +983,195 | 0.06% |
| BlackRock, Inc. | 7,002,530 | 8.92% | $260.56M | +1,632,645 | 0.00% |
| Kynam Capital Management, LP | 5,322,908 | 6.78% | $198.07M | −517,659 | 10.95% |
| Price T Rowe Associates Inc /Md/ | 4,685,223 | 5.97% | $174.34K | +2,598,891 | 0.02% |
| State Street Corp | 3,900,427 | 4.97% | $145.13M | +1,096,259 | 0.00% |
| FMR LLC | 3,722,888 | 4.74% | $138.53M | −26,160 | 0.01% |
| Vanguard Capital Management LLC | 3,464,831 | 4.41% | $128.93M | +503,936 | 0.00% |
| Deep Track Capital, LP | 2,939,151 | 3.74% | $109.37M | +1,655,172 | 1.59% |
| Logos Global Management LP | 2,100,000 | 2.67% | $78.14M | +1,650,000 | 3.36% |
| Geode Capital Management, LLC | 2,022,226 | 2.58% | $75.26M | +334,152 | 0.00% |
| Eversept Partners, LP | 1,785,941 | 2.27% | $66.45M | −2,075 | 3.45% |
| Goldman Sachs Group Inc | 1,615,343 | 2.06% | $60.11M | +626,927 | 0.01% |
| Assenagon Asset Management S.A. | 1,577,392 | 2.01% | $58.69M | +1,430,867 | 0.04% |
| Commodore Capital LP | 1,350,000 | 1.72% | $50.23M | −1,346,616 | 2.99% |
| Bellevue Group AG | 1,200,000 | 1.53% | $44.65M | – | 0.94% |
| Baker Bros. Advisors LP | 1,182,611 | 1.51% | $44.00M | +517,241 | 0.22% |
| Millennium Management LLC | 1,170,787 | 1.49% | $43.56M | −82,745 | 0.02% |
| Dimensional Fund Advisors LP | 1,073,985 | 1.37% | $39.96M | +14,451 | 0.01% |
| American Century Companies Inc | 1,042,395 | 1.33% | $38.79M | +186,085 | 0.02% |
| Eventide Asset Management, LLC | 1,037,000 | 1.32% | $38.59M | – | 0.52% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 253 | 86M | 100.0% | 49 / 106 | 57 / 21 | 22M | 9M |
| Q1 2026 | 228 | 73M | 92.7% | 59 / 68 | 58 / 14 | 13M | 9M |
| Q4 2025 | 186 | 73M | 93.3% | 25 / 59 | 59 / 21 | 9M | 6M |
| Q3 2025 | 184 | 71M | 90.3% | 31 / 60 | 56 / 26 | 7M | 9M |
| Q2 2025 | 180 | 72M | 92.2% | 38 / 74 | 43 / 28 | 8M | 10M |
| Q1 2025 | 171 | 74M | 93.8% | 29 / 64 | 52 / 31 | 10M | 10M |
| Q4 2024 | 174 | 74M | 93.8% | 34 / 65 | 49 / 36 | 13M | 11M |
| Q3 2024 | 176 | 72M | 91.5% | 23 / 66 | 56 / 29 | 15M | 8M |
| Q2 2024 | 183 | 70M | 88.9% | 25 / 81 | 49 / 36 | 7M | 8M |
| Q1 2024 | 197 | 70M | 89.3% | 47 / 80 | 44 / 13 | 17M | 9M |
| Q4 2023 | 164 | 62M | 78.8% | 33 / 61 | 44 / 11 | 13M | 2M |
| Q3 2023 | 143 | 51M | 64.4% | 15 / 61 | 42 / 21 | 5M | 3M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of CLDX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Health Care Fund | 3,783,994 | 4.82% | $144.02M | 0.38% | Jul 31, 2026 |
| Vanguard Total Stock Market Index Fund | 2,487,758 | 3.17% | $92.57M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 2,032,138 | 2.59% | $75.62M | 0.09% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 2,026,087 | 2.58% | $75.39M | 0.70% | Jun 30, 2026 |
| Vanguard Explorer Fund | 1,447,608 | 1.84% | $55.10M | 0.25% | Jul 31, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 1,254,603 | 1.60% | $46.68M | 0.32% | Jun 30, 2026 |
| Eventide Healthcare & Life Sciences Fund | 1,037,000 | 1.32% | $38.59M | 2.16% | Jun 30, 2026 |
| T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund | 970,814 | 1.24% | $36.12M | 0.37% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 897,530 | 1.14% | $33.40M | 0.03% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 854,702 | 1.09% | $32.53M | 0.10% | Jul 31, 2026 |
| Small Cap Growth Fund | 793,241 | 1.01% | $30.19M | 0.54% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 579,456 | 0.74% | $21.56M | 0.14% | Jun 30, 2026 |
| Federated Hermes Kaufmann Fund | 530,328 | 0.68% | $20.18M | 0.41% | Jul 31, 2026 |
| Fidelity Advisor Biotechnology Fund | 512,352 | 0.65% | $19.50M | 0.89% | Jul 31, 2026 |
| Strategic Advisers Fidelity U.S. Total Stock Fund | 512,299 | 0.65% | $16.10M | 0.01% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Anthony S. Marucci | PRESIDENT & CEO, Director | 40,284 | 0.05% | Jun 29, 2026 |
| Sarah Cavanaugh | SVP OF CORP AFFAIRS & ADMIN. | 12,610 | 0.02% | Jun 29, 2026 |
| Samuel Bates Martin | SVP AND CFO | 32,942 | 0.04% | Jun 29, 2026 |
| Margo Heath-Chiozzi | SVP OF REGULATORY AFFAIRS | 13,383 | 0.02% | Jun 29, 2026 |
| Diane C. Young | SVP, CHIEF MEDICAL OFFICER | 17,115 | 0.02% | Jun 29, 2026 |
| Freddy A. Jimenez | SVP & GENERAL COUNSEL | 30,796 | 0.04% | Jun 29, 2026 |
| Ronald Pepin | SR. VP & CBO | 20,097 | 0.03% | Jun 29, 2026 |
| Tibor Keler | EXECUTIVE VP & CSO | 24,217 | 0.03% | Jun 29, 2026 |
| Elizabeth Crowley | SR. VP & CPDO | 39,074 | 0.05% | Jun 29, 2026 |
| Teri L. Lawver | SVP & Chief Commercial Officer | – | – | Jun 29, 2026 |
| Cheryl Cohen | Director | – | – | Jun 29, 2026 |
| Rita Jain | Director | – | – | Jun 29, 2026 |
| Harry Penner Jr | Director | 41,916 | 0.05% | Jun 29, 2026 |
| Herbert J. Conrad | Director | 38,500 | 0.05% | Jun 29, 2026 |
| Keith L. Brownlie | Director | 10,000 | 0.01% | Jun 29, 2026 |
| James J. Marino | Director | 2,204 | 0.00% | Jun 29, 2026 |
| Garry Arthur Neil | Director | – | – | Jun 29, 2026 |
| Denice Torres | Director | – | – | Jun 29, 2026 |
| Richard M. Wright | – | 70,131 | 0.09% | Nov 17, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Samuel Bates Martin SVP AND CFO | Jan 2, 2026 | Option exercise | +4,817 | $10.38 | $50.00K | 32,942 |
| Ronald Pepin SR. VP & CBO | Dec 15, 2025 | Option exercise | +11,000 | $2.78 | $30.58K | 20,097 |
| Ronald Pepin SR. VP & CBO | Dec 15, 2025 | Option exercise | +8,333 | $9.02 | $75.16K | 9,097 |
| Freddy A. Jimenez SVP & GENERAL COUNSEL | Dec 4, 2025 | Sale | −4,166 | $29.10 | $121.23K | 30,796 |
| Richard M. Wright – | Nov 13, 2025 | Option exercise | +15,750 | $22.48 | $354.06K | 70,131 |
| Richard M. Wright – | Nov 13, 2025 | Option exercise | +26,672 | $10.38 | $276.86K | 54,381 |
| Richard M. Wright – | Nov 13, 2025 | Option exercise | +6,876 | $9.02 | $62.02K | 27,709 |
| Richard M. Wright – | Nov 13, 2025 | Sale | −49,298 | $24.00 | $1.18M | 20,833 |
| Freddy A. Jimenez SVP & GENERAL COUNSEL | Aug 13, 2025 | Sale | −430 | $25.42 | $10.93K | 34,962 |
| Freddy A. Jimenez SVP & GENERAL COUNSEL | Aug 13, 2025 | Sale | −341 | $23.95 | $8.17K | 35,392 |
| James J. Marino Director | Nov 18, 2024 | Gift | −10,500 | – | – | 2,204 |
| Anthony S. Marucci PRESIDENT & CEO, Director | Nov 11, 2024 | Buy | +11,500 | $26.82 | $308.43K | 40,284 |
| Samuel Bates Martin SVP AND CFO | Jun 14, 2024 | Option exercise | +3,201 | $9.02 | $28.87K | 28,329 |
| Samuel Bates Martin SVP AND CFO | Jun 14, 2024 | Option exercise | +16,968 | $10.38 | $176.13K | 45,297 |
| Samuel Bates Martin SVP AND CFO | Jun 14, 2024 | Sale | −17,172 | $35.42 | $608.23K | 28,125 |
| Elizabeth Crowley SR. VP & CPDO | Jun 14, 2024 | Option exercise | +30,000 | $10.38 | $311.40K | 39,074 |
| Elizabeth Crowley SR. VP & CPDO | Jun 14, 2024 | Sale | −30,000 | $34.87 | $1.05M | 9,074 |
| Diane C. Young SVP, CHIEF MEDICAL OFFICER | Jun 11, 2024 | Option exercise | +15,000 | $2.71 | $40.65K | 17,115 |
| Diane C. Young SVP, CHIEF MEDICAL OFFICER | Jun 7, 2024 | Sale | −45,000 | $35.26 | $1.59M | 2,115 |
| Elizabeth Crowley SR. VP & CPDO | Jun 7, 2024 | Option exercise | +7,500 | $10.38 | $77.85K | 16,574 |
| Elizabeth Crowley SR. VP & CPDO | Jun 7, 2024 | Sale | −15,000 | $35.06 | $525.90K | 9,074 |
| Elizabeth Crowley SR. VP & CPDO | Jun 7, 2024 | Option exercise | +7,500 | $9.02 | $67.65K | 24,074 |
| Freddy A. Jimenez SVP & GENERAL COUNSEL | Jun 5, 2024 | Option exercise | +9,540 | $10.38 | $99.03K | 35,464 |
| Margo Heath-Chiozzi SVP OF REGULATORY AFFAIRS | Jun 3, 2024 | Sale | −58,369 | $33.65 | $1.96M | 13,383 |
| Margo Heath-Chiozzi SVP OF REGULATORY AFFAIRS | Jun 3, 2024 | Option exercise | +58,369 | $10.38 | $605.87K | 71,752 |
| Margo Heath-Chiozzi SVP OF REGULATORY AFFAIRS | Jun 3, 2024 | Option exercise | +6,289 | $9.02 | $56.73K | 13,383 |
| Richard M. Wright SR. VP & CCO | Jun 3, 2024 | Option exercise | +28,469 | $28.00 | $797.13K | 49,302 |
| Richard M. Wright SR. VP & CCO | Jun 3, 2024 | Sale | −19,264 | $33.99 | $654.78K | 20,833 |
| Richard M. Wright SR. VP & CCO | Jun 3, 2024 | Option exercise | +20,625 | $2.78 | $57.34K | 20,833 |
| Richard M. Wright SR. VP & CCO | Jun 3, 2024 | Sale | −27,580 | $33.53 | $924.76K | 40,097 |
| Richard M. Wright SR. VP & CCO | Jun 3, 2024 | Option exercise | +18,375 | $22.48 | $413.07K | 67,677 |
| Freddy A. Jimenez SVP & GENERAL COUNSEL | Jun 3, 2024 | Sale | −8,006 | $33.60 | $269.00K | 25,924 |
| Freddy A. Jimenez SVP & GENERAL COUNSEL | Jun 3, 2024 | Option exercise | +8,006 | $10.38 | $83.10K | 33,930 |
| Elizabeth Crowley SR. VP & CPDO | May 30, 2024 | Sale | −38,597 | $33.64 | $1.30M | 9,074 |
| Elizabeth Crowley SR. VP & CPDO | May 30, 2024 | Option exercise | +34,445 | $2.78 | $95.76K | 39,171 |
| Elizabeth Crowley SR. VP & CPDO | May 30, 2024 | Option exercise | +8,500 | $9.02 | $76.67K | 47,671 |
| Sarah Cavanaugh SVP OF CORP AFFAIRS & ADMIN. | May 30, 2024 | Option exercise | +10,750 | $2.78 | $29.88K | 12,610 |
| Sarah Cavanaugh SVP OF CORP AFFAIRS & ADMIN. | May 30, 2024 | Option exercise | +10,103 | $9.02 | $91.13K | 22,713 |
| Sarah Cavanaugh SVP OF CORP AFFAIRS & ADMIN. | May 30, 2024 | Sale | −20,853 | $33.73 | $703.37K | 1,860 |
| Samuel Bates Martin SVP AND CFO | May 30, 2024 | Option exercise | +25,000 | $10.38 | $259.50K | 60,128 |
| Samuel Bates Martin SVP AND CFO | May 30, 2024 | Sale | −35,000 | $34.05 | $1.19M | 25,128 |
| Margo Heath-Chiozzi SVP OF REGULATORY AFFAIRS | May 30, 2024 | Sale | −38,719 | $34.07 | $1.32M | 7,094 |
| Margo Heath-Chiozzi SVP OF REGULATORY AFFAIRS | May 30, 2024 | Option exercise | +29,068 | $2.78 | $80.81K | 41,162 |
| Margo Heath-Chiozzi SVP OF REGULATORY AFFAIRS | May 30, 2024 | Option exercise | +2,043 | $9.02 | $18.43K | 43,205 |
| Margo Heath-Chiozzi SVP OF REGULATORY AFFAIRS | May 30, 2024 | Option exercise | +2,608 | $10.38 | $27.07K | 45,813 |
| Freddy A. Jimenez SVP & GENERAL COUNSEL | Feb 13, 2024 | Option exercise | +20,000 | $2.78 | $55.60K | 25,924 |
| Freddy A. Jimenez SVP & GENERAL COUNSEL | Feb 13, 2024 | Option exercise | +4,166 | $9.02 | $37.58K | 5,924 |
| Samuel Bates Martin SVP AND CFO | Jan 2, 2024 | Option exercise | +10,750 | $2.78 | $29.88K | 35,128 |
| Tibor Keler EXECUTIVE VP & CSO | Dec 7, 2022 | Option exercise | +16,860 | $2.78 | $46.87K | 24,217 |
| Tibor Keler EXECUTIVE VP & CSO | Dec 7, 2022 | Sale | −16,860 | $36.93 | $622.64K | 7,357 |
| Sarah Cavanaugh SVP OF CORP AFFAIRS & ADMIN. | Aug 18, 2022 | Sale | −1,355 | $36.38 | $49.29K | 1,284 |
| Sarah Cavanaugh SVP OF CORP AFFAIRS & ADMIN. | Aug 18, 2022 | Option exercise | +1,355 | $9.02 | $12.22K | 2,639 |
| Sarah Cavanaugh SVP OF CORP AFFAIRS & ADMIN. | Aug 17, 2022 | Option exercise | +31,312 | $2.78 | $87.05K | 32,596 |
| Sarah Cavanaugh SVP OF CORP AFFAIRS & ADMIN. | Aug 17, 2022 | Sale | −31,312 | $36.73 | $1.15M | 1,284 |
| Diane C. Young SVP, CHIEF MEDICAL OFFICER | Aug 17, 2022 | Option exercise | +19,000 | $10.38 | $197.22K | 21,115 |
| Diane C. Young SVP, CHIEF MEDICAL OFFICER | Aug 17, 2022 | Sale | −19,000 | $37.30 | $708.70K | 2,115 |
| Diane C. Young SVP, CHIEF MEDICAL OFFICER | Aug 17, 2022 | Option exercise | +45,000 | $2.71 | $121.95K | 47,115 |
| Anthony S. Marucci PRESIDENT & CEO, Director | Aug 15, 2022 | Option exercise | +45,000 | $9.02 | $405.90K | 147,692 |
| Anthony S. Marucci PRESIDENT & CEO, Director | Aug 15, 2022 | Option exercise | +75,000 | $2.78 | $208.50K | 102,692 |
| Anthony S. Marucci PRESIDENT & CEO, Director | Aug 15, 2022 | Sale | −120,000 | $37.66 | $4.52M | 27,692 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| A. Jimenez Freddy Officer | Dec 4, 2025 | 4,166 | $121.21K | Dec 4, 2025 | Exercised Shares |
| M. Wright Richard Officer | Nov 13, 2025 | 49,298 | $1.18M | Nov 13, 2025 | Stock Option Exercise |
| Samuel Bates Martin Officer | Jun 14, 2024 | 17,172 | $583.85K | Jun 14, 2024 | STOCK OPTION EXERCISE |
| Elizabeth Crowley Officer | Jun 14, 2024 | 30,000 | $1.02M | Jun 14, 2024 | STOCK OPTION EXERCISE |
| Diane C. Young Officer | Jun 7, 2024 | 45,000 | $1.59M | Jun 7, 2024 | EXERCISED SHARES |
| Elizabeth Crowley Officer | Jun 7, 2024 | 15,000 | $510.00K | Jun 7, 2024 | STOCK OPTION EXERCISE |
| Richard M. Wright Officer | Jun 3, 2024 | 46,844 | $1.50M | Jun 3, 2024 | STOCK OPTION EXERCISE |
| Freddy A. Jimenez Officer | Jun 3, 2024 | 8,006 | $269.00K | Jun 3, 2024 | STOCK OPTION EXERCISE |
| Margo Heath-Chiozzi Director | May 30, 2024 | 97,088 | $3.53M | May 30, 2024 | STOCK OPTION EXERCISE |
| Sarah Cavanaugh Officer | May 30, 2024 | 20,853 | $703.33K | May 30, 2024 | STOCK OPTION EXERCISE |
| Elizabeth Crowley Officer | May 30, 2024 | 38,597 | $144.00K | May 30, 2024 | STOCK OPTION EXERCISE |
| Samuel Bates Martin Officer | May 30, 2024 | 35,000 | $1.19M | May 30, 2024 | ESPP |